ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC

Zhejiang University

Status: Unknown

Conditions: Non-Small-Cell Lung Cancer Metastatic; EGFR Wildtype; Non-small Cell Lung Cancer Stage III; Adenocarcinoma of Lung

Treatments: Genetic: ctDNA analysis

Study type: Observational

Funder types: Other

Identifiers

NCT02946216

2016-101-01

Details and patient eligibility

About

The study aims to explore the prevalence of ALK/ROS1/MET mutations assessed with ctDNA samples in EGFR-wildtype NSCLC

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed stage IIIB/IV NSCLC;
• Histologically confirmed adenocarcinoma;
• EGFR-wildtype NSCLC;
• Provision of blood (plasma) sample for ctDNA testing;
• Patient must be able to comply with the protocol;
• Provision of blood (plasma) sample for ctDNA testing;

Exclusion criteria

• As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease);
• Histologically confirmed small cell lung cancer or other metastatic tumors;
• Patient with no histologic or cytological diagnosis;